DUR-928

Phase 2Small molecule

DDurect

DUR-928 is one of 114 small molecule programs targeting Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Kidney InjuryActive, not recruiting

PsoriasisActive, not recruiting

Sclerosing CholangitisActive, not recruiting

HepatitisPhase 2

Active, not recruiting

Kidney InjuryPhase 2

Active, not recruiting

PsoriasisPhase 2

Active, not recruiting

Sclerosing CholangitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Preclinical

53 2

Stelara

Johnson & Johnson

Preclinical

37 3

Taltz

Eli Lilly

Preclinical

20 4

Humira

CCelltrion

Preclinical

42 5

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 6

Raptiva

Roche

Preclinical

10 7

DUR-928

DDurect

Phase 2

1 8

Siliq

BBausch Health Americas, Inc.

Preclinical

14 9

Victoza

Novo Nordisk

Preclinical

2 10

Olux

HHarrow Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatitis3 trials

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

Completed·DDurect·Phase 2·NCT04563026·307 enrolled

DUR-928 in Patients With Alcoholic Hepatitis

Completed·CCraig James McClain·Phase 2·NCT03917407·43 enrolled

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

Completed·DDurect·Phase 2·NCT03432260·19 enrolled

Kidney Injury1 trial

DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

Terminated·DDurect·Phase 2·NCT04447404·2 enrolled

Sclerosing Cholangitis1 trial

A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

Terminated·DDurect·Phase 2·NCT03394781·5 enrolled

Psoriasis1 trial

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

Completed·DDurect·Phase 2·NCT03837743·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for DUR-928. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DUR-928 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DUR-928. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Durect company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDurect

DUR-928

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatitis3 trials

Kidney Injury1 trial

Sclerosing Cholangitis1 trial

Psoriasis1 trial

References

Drug Info

Quick Facts

Related News